Exosome Platform Chip Diagnostics offers an innovative hardware and AI-informed platform for exosome profiling to develop biomarker signatures, presenting a compelling selling point to pharma and diagnostics teams seeking rapid, multi-disease fingerprinting capabilities.

Early Diagnostics The focus on early disease diagnostics and therapy management creates opportunities to target biopharma, clinical labs, and CROs looking to improve early detection workflows and patient stratification.

Low-Cost Workflow Emphasize the potential for inexpensive, less resource-intensive workflows compared to traditional methods, appealing to cost-conscious labs and large-scale screening projects.

Scalable Data Platform Highlight the data/AI informatics stack as a differentiator for integrating exosome signatures into existing data ecosystems, enabling seamless analytics, reporting, and decision support.

Growth Potential Despite a small team, presentation of traction through proprietary workflow and niche exosome targeting positions Chip Diagnostics for partnerships, licensing, or early-stage strategic collaborations with larger players in life sciences.